• May 9, 2012Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2012)
• April 20, 2012Launch of "AIPHAGANR Ophthalmic Solution 0.1%" for the treatment of Glaucoma / Ocular Hypertension, in Japan
• February 3, 2012Third Quarter Consolidated Financial Results for the Ending Fiscal Year March 31, 2012
• February 3, 2012Summary of Consolidated Financial Results(For the Third Quarter Ended December 31, 2011) [Japanese Standard]
• November 8, 2011Kyorin Pharmaceutical and Daiichi Sankyo Brasil Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
• November 8, 2011Summary of Consolidated Financial Results (For the Second Quarter Ended september 30,2011)［Japanese Standard］
• November 8, 2011Consolidated Financial Results (For the Second Quarter Ended september 30,2011)- Supplementary Information
• August 22, 2011First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012
• August 11, 2011Summary of Consolidated Financial Results(For the First Quarter Ended June 30, 2011)
• May 11, 2011Financial Results for the Fiscal 2010, the Year Ended March 31, 2011- Supplementary Information
• May 11, 2011Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2011)
• April 5, 2011Release of "Uritos® OD Tablets 0.1mg" a Drug for Overactive Bladder
• February 24, 2011Kyorin signed a License Agreement with Almirall on COPD Therapeutic Agent "Aclidinium Bromide" for Japan Territory
• February 21, 2011KYORIN Group's Participation in Environmental Hygiene
• February 15, 2011Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2011
• February 8, 2011Summary of Consolidated Financial Results (For the Third Quarter Ended December 31, 2010) [Japanese Standard]
• November 17, 2010Summary of Consolidated Financial Results (For the Second Quarter Ended September 30,2010)[Japanese Standard]
• November 12, 2010Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
• November 8, 2010Extension of License Rights Regarding KRP-203
• September 21, 2010Regarding Today's Media Report
• July 30, 2010First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2011
• June 8, 2010RELEASE OF "MUCODYNE® DS50%"
• May 26, 2010Change of Business Name
• May 26, 2010New Medium-Term Business Plan Developed: "HOPE 100 Stage 1"
• February 3, 2010Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
• January 18, 2010MARKETING APPROVAL FOR "MUCODYNE® DS50%"
• January 7, 2010Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
• November 5, 2009Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
• September 29, 2009KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
• August 5, 2009First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
• July 27, 2009Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China
• April 3, 2009Change of Representative Director and President at KYORIN Pharmaceutical
• April 3, 2009Change of Representative Director and President at KYORIN
• March 19, 2009KYORIN Announces Dissolution of Subsidiary
• March 19, 2009KYORIN Subsidiary (Investment LPS) to Be Dissolved
• February 27, 2009Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
• February 5, 2009Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2009
• February 4, 2009KYORIN Updates Credit Rating from R&I
• January 29, 2009Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008
• December 24, 2008Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase

1 2